This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fitzpatrick, S. L. Articles by Schultz, G. S. Search for Related Content PubMed PubMed Citation Articles by Fitzpatrick, S. L. Articles by Schultz, G. S.

Epidermal Growth Factor Binding by Breast Tumor Biopsies and Relationship to Estrogen Receptor and Progestin Receptor Levels¹

Departments of Biochemistry [S. L. F., J. B., J. L. W., G. S. S.] and Pathology [G. B.], University of Louisville, Louisville, Kentucky 40292

Epidermal growth factor (EGF) may be important in regulating the growth of some breast cancer cells in vivo because of its mitogenic action on some breast cancer cell lines in vitro. Epidermal growth factor receptors (EGF-R) were measured in a series of breast tumors to determine what percentage of breast tumors express EGF-R and whether EGF-R was independent of expression of estrogen receptor and progestin receptor. Specific binding of ¹²⁵I-EGF to membranes from pooled homogenates of breast tumors reached equilibrium after 45 min at 25° and remained constant. Scatchard analysis of ¹²⁵I-EGF binding indicated a single class of receptors with an apparent K_d of 2 nM and a binding capacity of 28 fmol/mg of membrane protein, and the binding of ¹²⁵I-EGF was not effectively competed for by insulin, fibroblast growth factor, growth hormone, or prolactin. Specific binding of ¹²⁵I-EGF of 1 fmol or greater/mg of membrane protein and 15% or greater specific binding was detected in 48% of 137 unselected primary and metastatic breast tumors. The frequency distribution of EGF binding values was unimodal, with a progressive decrease in the proportion of patients with high EGF binding values. The values of EGF binding ranged from 1 to 121 fmol/mg of protein, with an arithmetic mean of 8.4 fmol/mg of protein and a geometric mean of 3.2 fmol/mg of protein. Forty-two % of 24 metastatic breast tumors were positive for EGF binding, with an arithmetic mean of 6.3 fmol/mg of protein and a geometric mean of 4.1 fmol/mg of protein. The magnitude of EGF binding in individual tumors was independent of either estrogen receptor or progestin receptor levels, although the highest quantities of EGF binding were expressed by tumors lacking steroid receptors. Approximately 20% of the tumors in the study were EGF-R-positive and ER-negative, suggesting that the growth of these tumors may be regulated predominantly by a peptide hormone (EGF) rather than a steroid hormone (estrogen). EGF binding did not correlate significantly with age of the patients. Correlation analysis between EGF binding and the percentage of malignant and nonmalignant cell types present in sections of tumor adjacent to the area assayed for EGF binding indicated that the percentage of malignant cells is an important factor in determining the amount of EGF binding in tumor homogenates. The recent discovery of transforming growth factors which interact with the EGF-receptor system suggests additional roles for EGF receptors in breast cancer.

¹ Supported by NIH Grants CA 31895 and CA-19657 from the National Cancer Institute.

² Current address: Graduate School of Biomedical Sciences, University of Texas Health Sciences Center, Houston, TX 77030.

³ To whom requests for reprints should be addressed, at Department of Biochemistry, University of Louisville, Louisville, KY 40292.

Received 9/23/83. Accepted 4/17/84.

This article has been cited by other articles:

				J. L. Boerner, M. A. Gibson, E. M. Fox, E. D. Posner, S. J. Parsons, C. M. Silva, and M. A. Shupnik Estrogen Negatively Regulates Epidermal Growth Factor (EGF)-Mediated Signal Transducer and Activator of Transcription 5 Signaling in Human EGF Family Receptor-Overexpressing Breast Cancer Cells Mol. Endocrinol., November 1, 2005; 19(11): 2660 - 2670. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				R. Lu and G. Serrero Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468 PNAS, April 11, 2000; 97(8): 3993 - 3998. [Abstract] [Full Text] [PDF]

				M. B. Vrouenraets, G. W. M. Visser, F. A. Stewart, M. Stigter, H. Oppelaar, P. E. Postmus, G. B. Snow, and G. A. M. S. van Dongen Development of meta-Tetrahydroxyphenylchlorin-Monoclonal Antibody Conjugates for Photoimmunotherapy Cancer Res., April 1, 1999; 59(7): 1505 - 1513. [Abstract] [Full Text] [PDF]

				J. Wiesen, P Young, Z Werb, and G. Cunha Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development Development, January 1, 1999; 126(2): 335 - 344. [Abstract] [PDF]

				S. Galandiuk, S. Miseljic, A.-R. Yang, M. Early, M. D. McCoy, and J. L. Wittlijf Expression of Hormone Receptors, Cathepsin D, and HER-2/neu Oncoprotein in Normal Colon and Colonic Disease Arch Surg, June 1, 1993; 128(6): 637 - 642. [Abstract] [PDF]

				S. J. Bradley, G. Garfinkle, E. Walker, R. Salem, L. B. Chen, and G. Steele Jr Increased Expression of the Epidermal Growth Factor Receptor on Human Colon Carcinoma Cells Arch Surg, November 1, 1986; 121(11): 1242 - 1247. [Abstract] [PDF]